000298594 001__ 298594
000298594 005__ 20250511020418.0
000298594 0247_ $$2doi$$a10.1158/2643-3230.BCD-24-0178
000298594 0247_ $$2pmid$$apmid:39913291
000298594 0247_ $$2ISSN$$a2643-3230
000298594 0247_ $$2ISSN$$a2643-3249
000298594 0247_ $$2altmetric$$aaltmetric:174083404
000298594 037__ $$aDKFZ-2025-00304
000298594 041__ $$aEnglish
000298594 082__ $$a610
000298594 1001_ $$0P:(DE-He78)31f8eac7b031fdafb391c06ba0ea992e$$aLiebers, Nora$$b0$$eFirst author
000298594 245__ $$aBrexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma.
000298594 260__ $$aPhiladelphia, PA$$bAmerican Association for Cancer Research$$c2025
000298594 3367_ $$2DRIVER$$aarticle
000298594 3367_ $$2DataCite$$aOutput Types/Journal article
000298594 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1746604547_3748
000298594 3367_ $$2BibTeX$$aARTICLE
000298594 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000298594 3367_ $$00$$2EndNote$$aJournal Article
000298594 500__ $$a#EA:B340# / 2025 May 5;6(3):182-190
000298594 520__ $$aBrexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed or refractory mantle cell lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an analysis of 64 r/r MCL patients aged ≥50 years treated with brexu-cel in the ZUMA-2 study, matching them 1:1 by propensity score to 64 (out of 272) r/r MCL patients who underwent alloHCT using data from the EBMT registry. Median follow-up time was 36.5 and 34.1 months for the brexu-cel and matched alloHCT cohort, respectively. Brexu-cel patients had a significantly higher overall survival (OS, 81.3% vs 59.2%, HR: 0.39, p=0.004) and lower non-relapse mortality (3.6% vs 21.2%, p=0.015) one year after treatment. Chronic graft-vs-host disease occurred in 26.9% of alloHCT patients within the first year. However, long-term progression-free survival and OS remain comparable. Despite limitations of this non-randomized study, it indicates a superior safety profile for brexu-cel in r/r MCL.
000298594 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000298594 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000298594 7001_ $$00000-0002-2552-0542$$aBoumendil, Ariane$$b1
000298594 7001_ $$aFinel, Hervé$$b2
000298594 7001_ $$0P:(DE-He78)92820b4867c955a04f642707ecf35b40$$aEdelmann, Dominic$$b3$$udkfz
000298594 7001_ $$00000-0002-9745-8813$$aKobbe, Guido$$b4
000298594 7001_ $$00009-0000-1699-9478$$aBaermann, Ben-Niklas$$b5
000298594 7001_ $$00000-0001-8751-5725$$aSerroukh, Yasmina$$b6
000298594 7001_ $$00000-0002-5684-9447$$aBlaise, Didier$$b7
000298594 7001_ $$00000-0001-5050-220X$$aBeelen, Dietrich Wilhelm$$b8
000298594 7001_ $$00000-0003-3702-0817$$aSolano, Carlos$$b9
000298594 7001_ $$00000-0001-5844-1632$$aItälä-Remes, Maija$$b10
000298594 7001_ $$00000-0002-5581-6950$$avan Meerten, Tom$$b11
000298594 7001_ $$00009-0007-2067-9750$$aChoi, Goda$$b12
000298594 7001_ $$00009-0001-5941-3673$$aSchmidt, Susanne A C$$b13
000298594 7001_ $$00000-0001-5103-9966$$aKröger, Nicolaus$$b14
000298594 7001_ $$00009-0004-7576-2787$$aByrne, Jenny$$b15
000298594 7001_ $$00000-0003-4879-8106$$aTudesq, Jean-Jacques$$b16
000298594 7001_ $$00000-0001-6722-0065$$aOssami Saidy, Anna$$b17
000298594 7001_ $$00009-0004-7481-9550$$aNunes, Ana$$b18
000298594 7001_ $$00000-0003-0244-1531$$aSiddiqi, Rubina$$b19
000298594 7001_ $$00009-0004-8566-6828$$aBaro, Elande$$b20
000298594 7001_ $$00009-0005-6516-1723$$aZheng, Dan$$b21
000298594 7001_ $$00009-0004-3243-8450$$aKloos, Ioana$$b22
000298594 7001_ $$00000-0002-7429-8570$$aDreger, Peter$$b23
000298594 7001_ $$00000-0002-1238-6970$$aSureda, Anna$$b24
000298594 7001_ $$00009-0000-0816-688X$$aGlass, Bertram$$b25
000298594 7001_ $$aDietrich, Sascha$$b26
000298594 773__ $$0PERI:(DE-600)3028898-8$$a10.1158/2643-3230.BCD-24-0178$$n3$$p182-190$$tBlood cancer discovery$$v6$$x2643-3230$$y2025
000298594 909CO $$ooai:inrepo02.dkfz.de:298594$$pVDB
000298594 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)31f8eac7b031fdafb391c06ba0ea992e$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000298594 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92820b4867c955a04f642707ecf35b40$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000298594 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000298594 9141_ $$y2025
000298594 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBLOOD CANCER DISCOV : 2022$$d2024-12-06
000298594 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-06
000298594 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-06
000298594 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-06
000298594 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-06
000298594 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-06
000298594 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bBLOOD CANCER DISCOV : 2022$$d2024-12-06
000298594 9201_ $$0I:(DE-He78)B340-20160331$$kB340$$lTranslationale Medizinische Onkologie$$x0
000298594 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000298594 9200_ $$0I:(DE-He78)B340-20160331$$kB340$$lTranslationale Medizinische Onkologie$$x0
000298594 980__ $$ajournal
000298594 980__ $$aVDB
000298594 980__ $$aI:(DE-He78)B340-20160331
000298594 980__ $$aI:(DE-He78)C060-20160331
000298594 980__ $$aUNRESTRICTED